-
2022-501361-44-00
5
Adult patients of either gender with active moderate to severe rheumat
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-514246-37-00
4
Idiopathic pulmonary fibrosis (IPF)
-
2024-518420-80-00
5
Primary infection prophylaxis for secondary immunodeficiency (SID) in
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521908-22-00
10
EGFR-mutated Non-small Cell Lung Cancer
-
2025-522983-33-00
5
Chronic rhinosinusitis with nasal polyps
-
2025-523811-12-00
10
Achondroplasia
-
2025-524241-27-00
5
Treatment-naїve mantle cell lymphoma (MCL)
-
2025-524289-56-00
6
Asthma
-
2025-525158-20-00
1
Stage IIB/C, Stage III, or Stage IV Melanoma
-
2025-524090-16-00
7
2026-06-24
Relapsed/Refractory Small Cell Lung Cancer
-
2025-520565-51-00
5
2026-06-23
small cell lung cancer
-
2025-523576-23-00
5
2026-06-12
Unresectable Stage III non-small cell lung cancer without progression
-
2025-523586-18-00
5
2026-06-11
Non-Small Cell Lung Cancer
-
2025-521950-41-00
5
2026-06-05
severe uncontrolled asthma
-
2024-511496-14-00
5
2026-05-14
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2025-523180-38-00
4
2026-05-12
Uncontrolled Moderate to Severe Eosinophilic Asthma
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-523742-27-00
9
2026-04-28
Advanced solid tumors
-
2025-523202-32-00
5
2026-02-26
Major Depressive Disorder
-
2025-521919-39-00
3
2026-02-10
Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment